Patents by Inventor Roger Trinh
Roger Trinh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240082245Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: November 3, 2023Publication date: March 14, 2024Inventors: Christine Collins, Bo Fu, Abhishek Gulati, Jens Kort, Matthew Kosloski, Yang Lei, Chih-Wei Lin, Ran Liu, Federico Mensa, Iok Chan NG, Tami Pilot-Matias, David Pugatch, Nancy S. Shulman, Roger Trinh, Rolando M. Viani, Stanley Wang, Zhenzhen Zhang
-
Publication number: 20200368229Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: August 2, 2017Publication date: November 26, 2020Applicant: AbbVie Inc.Inventors: Christine Collins, Bo Fu, Abhishek Gulati, Jens Kort, Matthew Kosloski, Yang Lei, Chih-Wei Lin, Ran Liu, Federico Mensa, Iok Chan Ng, Tami Pilot-Matias, David Pugatch, Nancy S. Shulman, Roger Trinh, Rolando M. Viani, Stanley Wang, Zhenzhen Zhang
-
Publication number: 20200330460Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: August 30, 2018Publication date: October 22, 2020Applicant: AbbVie Inc.Inventors: Christine Collins, Emily O. Dumas, Bo Fu, Abhishek Gulati, Yiran Bonnie Hu, Jens Kort, Matthew Kosloski, Preethi Krishnan, Yang Lei, Chih-Wei Lin, Ran Liu, Frederico Mensa, Iok Chan Ng, Tami Pilot-Matias, David Pugatch, Susan Rhee, Nancy S. Shulman, Roger Trinh, Rolando M. Viani, Stanley Wang, Zhenzhan Zhang
-
Publication number: 20200222397Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 16 weeks, alternatively no more than 12 weeks, or alternatively no more than 8 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 16, 12, or 8 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: July 20, 2018Publication date: July 16, 2020Applicant: AbbVie Inc.Inventors: Christine Collins, Bo Fu, Abhishek Gulati, Jens Kort, Matthew Kosloski, Yang Lei, Chih-Wei Lin, Ran Liu, Federico Mensa, Iok Chan Ng, Tami Pilot-Matias, David Pugatch, Nancy S. Shulman, Roger Trinh, Rolando M. Viani, Stanley Wang, Zhenzhen Zhang
-
Publication number: 20180042982Abstract: The present invention generally features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 16, 12 or 8 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of interferon, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof. Further, additional compounds such as sofosbuvir, or its pharmaceutically acceptable salt may be used for retreatment of HCV patients who have failed glecaprevir and pibrentasvir combination therapy.Type: ApplicationFiled: October 12, 2017Publication date: February 15, 2018Applicant: AbbVie Inc.Inventors: Walid M. Awni, Barry M. Bernstein, Andrew L. Campbell, Sandeep Dutta, Chih-Wei Lin, Wei Liu, Tami Pilot-Matias, Rajeev M. Menon, Sven Mensing, Thomas J. Podsadecki, Lino Rodrigues Junior, Suvajit Samanti, Roger Trinh, Tianli Wang, Betty B. Yao
-
Publication number: 20170360783Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 16 weeks, alternatively no more than 12 weeks, or alternatively no more than 8 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 16, 12, or 8 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: September 1, 2017Publication date: December 21, 2017Applicant: AbbVie Inc.Inventors: Christine Collins, Emily O. Dumas, Bo Fu, Abhishek Gulati, Yiran Bonnie Hu, Jens Kort, Matthew Kosloski, Preethi Krishnan, Yang Lei, Chih-Wei Lin, Ran Liu, Federico Mensa, Iok Chan Ng, Tami Pilot-Matias, David Pugatch, Susan Rhee, Nancy S. Shulman, Roger Trinh, Rolado M. Viani, Stanley Wang, Zhenzhen Zhang
-
Publication number: 20150209403Abstract: This application features dose adjustment for drugs co-administered with Compound 1, Compound 2 and/or Compound 3.Type: ApplicationFiled: January 27, 2015Publication date: July 30, 2015Inventors: Walid M. Awni, Prajakta Badri, Daniel E. Cohen, Sandeep Dutta, Amit Khatri, Rajeev M. Menon, Thomas Podsadecki, Akshanth Polepally, Roger Trinh, Tianli Wang, Jiuhong Zha